THIS WEEK'S FEATURE
Closely-held CellMax Life has developed FirstSightCRC, the first blood test to identify precancerous adenomas, with accuracy similar to colonoscopies, when prevention of colorectal cancer (CRC) is possible.
With the FDA’s 510(k) clearance of its PURE EP System in August 2018 and first successful patient cases, BioSig (NASDAQ:BSGM) is advancing its vision to improve medicine through biomedical signal processing.
Closely-held NuPulseCV is enrolling patients with advanced heart failure in a feasibility study with its intravascular ventricular assist system (iVAS), a minimally invasive heart pump designed to allow patients to be discharged from hospital and resume their daily activities.
Closely-held Vessi Medical wants to change the standard of care for superficial bladder cancer by using a surface cryotherapy approach in a minimally invasive in-office treatment alternative to surgery.
After recently conducting five first-in-man coronary stent procedures robotically in India, Corindus Vascular Robotics (NASDAQ:CVRS) plans to perform its first remote vascular cases in the U.S. in mid-2019, leading to a potential product launch in 2020.